You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 6 Next »

TOBA-211 - Getting issue details... STATUS TOBA-212 - Getting issue details... STATUS This example assumes a simple parallel design in which the sponsor-defined protocol specifies the following information. All subjects are to be screened for 7 days prior to randomization into 3 protocol groups:

  • Group 1 is a control group of 20 subjects, 10 male and 10 female, dosed with vehicle once per day for 28 days.
  • Group 2 is a low-dose group of 20 subjects, 10 male and 10 female, dosed at 100 mg/kg once per day for 28 days.
  • Group 3 is a high-dose group of 20 subjects, 10 male and 10 female, dosed at 500 mg/kg once per day for 28 days.

There are no other experimental factors of interest specified in the study design. In this case, the design consists of 3 trial arms, because there are 3 distinct sequences of elements, depicted as follows:

TOBA-210 - Getting issue details... STATUS

ta.xpt

ta.xpt

RowSTUDYIDDOMAINARMCDARMTAETORDETCDELEMENTTABRANCHEPOCH
1EXP1TA1Control1SCRNScreenRandomized to Group 1Screen
2EXP1TA1Control2TRT01Vehicle Control
Treatment
3EXP1TA2100 mg/kg1SCRNScreenRandomized to Group 2Screen
4EXP1TA2100 mg/kg2TRT02100 mg/kg Drug A
Treatment
5EXP1TA3500 mg/kg1SCRNScreenRandomized to Group 3Screen
6EXP1TA3500 mg/kg2TRT03500 mg/kg Drug A
Treatment
$warningHtml

  • No labels